Since HCC is a potential terminal outcome of NAFLD, we compared mRNA expression levels of healthy against HCC tissue for DNTTIP2, ZNF326 and LMO7 next to the published HCC biomarker candidate H2AFY in data from the cancer genome atlas liver hepatocellular carcinoma database (n = 50; Figure 4B, last accessed 29 November 2021). Here, LMO7 is linked to metabolic dysfunction-associated steatotic liver disease.